On October 5, 2022 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, in second-line gastroesophageal junction/gastric (GEJ/G) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022 (Press release, Leap Therapeutics, OCT 5, 2022, View Source [SID1234621733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leap will also present preclinical DKN-01 data supporting the DeFianCe Study, a Phase 2 study of DKN-01 in combination with bevacizumab and standard of care chemotherapy in patients with advanced colorectal cancer who have received one prior systemic therapy.